DYV702

DYV702 is an investigational **transdermal pH-modulating** topical drug candidate developed by **Dyve Biosciences** using the company's DMAX transdermal delivery platform. It is formulated as a patented **cream** designed to deliver **pH-adjusting buffering agents through the skin** to reduce acidic microenvironments associated with inflammatory disease states. The lead disclosed clinical use is treatment of **pain associated with acute gout flares**, where a Phase 2 TARGETS study in 2022 reported reductions in pain intensity and duration, faster symptom resolution, improved physical function, and reduced rescue medication use, with mainly mild-to-moderate adverse events. The precise molecular target has not been publicly defined; its pharmacologic concept is local modulation of tissue acidity rather than classic receptor-specific binding.

Other names

DYV-702DYV702DYV 702